- Trials with a EudraCT protocol (219)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
219 result(s) found for: West syndrome.
Displaying page 1 of 11.
EudraCT Number: 2006-004286-33 | Sponsor Protocol Number: 1042-0501 | Start Date*: 2007-05-11 | |||||||||||
Sponsor Name:Marinus Pharmceuticals, Inc. | |||||||||||||
Full Title: An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spasms. | |||||||||||||
Medical condition: Infantile spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000611-17 | Sponsor Protocol Number: LTS12745 | Start Date*: 2017-08-28 | |||||||||||
Sponsor Name:Alfresa Pharma Corporation and Sanofi KK | |||||||||||||
Full Title: A Long term study of M071754 - A open-label study in patients with infantile spasms. | |||||||||||||
Medical condition: Patients diagnosed with infantile spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000230-62 | Sponsor Protocol Number: EFC12369 | Start Date*: 2017-04-24 | |||||||||||
Sponsor Name:Alfresa Pharma Corporation and Sanofi KK | |||||||||||||
Full Title: A Phase III study of M071754 - A single-blind study in patients with infantile spasms. | |||||||||||||
Medical condition: Patients diagnosed with infantile spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004285-13 | Sponsor Protocol Number: 1042-0500 | Start Date*: 2007-05-11 | |||||||||||
Sponsor Name:Marinus Pharmaceuticals, Inc. | |||||||||||||
Full Title: A double-blind, placebo-controlled, dose-ranging clinical study to evaluate the safety, tolerability, and antiepileptic activity of ganaxolone in treatment of patients with infantile spasms. | |||||||||||||
Medical condition: Infantile spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004904-50 | Sponsor Protocol Number: GWEP15100 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Cannabidiol (GWP42003-P) in infants with Infantile Spasms following an initial open label pilot study. | |||||||||||||
Medical condition: Infantile Spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003015-26 | Sponsor Protocol Number: AMZ002-002 | Start Date*: 2022-04-12 | |||||||||||||||||||||
Sponsor Name:Amzell B.V. | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms | |||||||||||||||||||||||
Medical condition: Monotherapy for the treatment of infantile spasms (IS) in infants and children 2 months to 24 months of age | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) FR (Ongoing) PL (Prematurely Ended) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002107-26 | Sponsor Protocol Number: EP0078 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: AN OPEN-LABEL ADAPTIVE STUDY FOR THE ASSESSMENT OF SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF RADIPRODIL IN SUBJECTS WITH DRUG-RESISTANT INFANTILE SPASMS | |||||||||||||
Medical condition: Infantile spasms (IS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000360-17 | Sponsor Protocol Number: TGO-VGB-III-01 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:TARGEON | ||||||||||||||||||
Full Title: Acceptability study of a new paediatric form of vigabatrin in infants and children with infantile spasms or pharmaco-resistant partial epilepsy. Observational, descriptive, open-label, multi-centr... | ||||||||||||||||||
Medical condition: Infantile spasms and pharmaco-resistant partial epilepsy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000355-27 | Sponsor Protocol Number: 995 | Start Date*: 2016-03-10 | |||||||||||
Sponsor Name:University Hospitals of North Midlands NHS Trust | |||||||||||||
Full Title: The effect on Endothelial progenitor cells (EPCs) by statin loading in “all comers” with an Acute Coronary Syndrome (ACS). | |||||||||||||
Medical condition: Acute Coronary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001650-26 | Sponsor Protocol Number: ZOL6700 | Start Date*: 2019-10-25 |
Sponsor Name:Hospital South West Jutland | ||
Full Title: Zoledronic acid for prevention of bone loss after bariatric surgery | ||
Medical condition: Morbid obese subjects undergoing bariatric surgery | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000184-32 | Sponsor Protocol Number: 205203 | Start Date*: 2017-09-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622 | |||||||||||||
Medical condition: Hypereosinophilic syndrome (HES) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) FR (Completed) PL (Completed) Outside EU/EEA IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005692-39 | Sponsor Protocol Number: 217013 | Start Date*: 2022-08-03 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES) | |||||||||||||
Medical condition: Hypereosinophilic Syndrome (HES) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001331-31 | Sponsor Protocol Number: ZX008-1900 | Start Date*: 2019-11-07 | ||||||||||||||||
Sponsor Name:Zogenix International Limited | ||||||||||||||||||
Full Title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such a... | ||||||||||||||||||
Medical condition: Dravet syndrome or Lennox-Gastaut syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DK (Completed) FR (Completed) ES (Ongoing) DE (Completed) SE (Completed) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022655-29 | Sponsor Protocol Number: RATE-trial | Start Date*: 2011-05-30 |
Sponsor Name:Erasmus MC | ||
Full Title: Randomised open label cross-over study into the efficacy of RApamycin in children with Tuberous sclerosis complex with intractable Epilepsy (RATE-trial) | ||
Medical condition: Epilepsy in children with Tuberous Sclerosis Complex | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000008-34 | Sponsor Protocol Number: 07.IBS.1 | Start Date*: 2007-09-13 | |||||||||||
Sponsor Name:North West London Hospitals NHS Trust | |||||||||||||
Full Title: Bacteria and host immune response as factors modulating visceral afferent processing in Irritable Bowel Syndrome: manipulation of visceral hypersensitivity with probiotic bacteria | |||||||||||||
Medical condition: Irritable Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002658-19 | Sponsor Protocol Number: 20016-01 | Start Date*: 2018-06-25 |
Sponsor Name:Department für Kinder- und Jugendheilkunde, Pädiatrie I | ||
Full Title: Influence of pulsatile dexamethasone therapy in childhood epilepsia on the immune Systeme. | ||
Medical condition: Analization of specific immune cells and immune modulation factors in children under pulsatile dexamethasone-therapy. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000657-50 | Sponsor Protocol Number: PM1116197 | Start Date*: 2014-05-27 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||||||||||||
Full Title: A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197)... | ||||||||||||||||||||||||||||
Medical condition: | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Completed) NL (Prematurely Ended) IT (Completed) DE (Completed) BE (Completed) SK (Completed) DK (Completed) ES (Completed) NO (Completed) GB (Completed) CZ (Completed) HU (Completed) EE (Completed) GR (Prematurely Ended) PL (Completed) BG (Completed) RO (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000838-39 | Sponsor Protocol Number: MHE104317 | Start Date*: 2007-10-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Resaearch and Development Ltd | |||||||||||||
Full Title: A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome | |||||||||||||
Medical condition: Hypereosinophilic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NO (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) PL (Trial now transitioned) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001076-34 | Sponsor Protocol Number: ABNL-MARRO-001 | Start Date*: 2023-06-12 | ||||||||||||||||
Sponsor Name:Theradex (Europe) Ltd. | ||||||||||||||||||
Full Title: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes | ||||||||||||||||||
Medical condition: Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015512-17 | Sponsor Protocol Number: PMA112509 | Start Date*: 2010-01-15 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS) | |||||||||||||
Medical condition: Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) DK (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
